© 2024 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Latest Conference Articles
Biosimilars Present Distinct Challenges in Rheumatology Practice
Kelly Davio
November 7 2017
American College of Rheumatology Annual Meeting
In a presentation titled “Biosimilar Medicine: Changing Landscape in Health Care,” given on Monday at the 2017 American College of Rheumatology Annual Meeting in San Diego, California, J. Eugene Huffstutter MD, FACP, FACR, shared practical considerations for using biosimilars in the rheumatology clinic.
Research Focuses on Proposed Adalimumab Biosimilars
Jackie Syrop
November 6 2017
American College of Rheumatology Annual Meeting
Three presentations at this week’s 2017 American College of Rheumatology Annual Meeting in San Diego, CA, cover research on pharmacokinetic equivalence, safety, and switching of 2 proposed adalimumab biosimilars, GP2017 and CHS-1420.
2 Surveys Highlight Rheumatologists' Knowledge Gaps With Biosimilars
Kelly Davio
November 6 2017
American College of Rheumatology Annual Meeting
Two posters presented today at the American College of Rheumatology’s 2017 meeting in San Diego, California, highlight the gaps in US rheumatologists’ knowledge concerning biosimilar therapies, and underscore the importance of greater physician education about biosimilar medicines.
Phase 3 Study Confirms Clinical Equivalence for ABP 980 and Reference Trastuzumab
Theodore Bosworth
October 4 2017
Complete phase 3 data show that a biosimilar almost beat reference trastuzumab (Herceptin) for the primary endpoint of pathologic complete response in patients with HER2-positive early breast cancer.
Federal Perspective on the Biosimilar Influence on Drug Costs
Surabhi Dangi-Garimella, PhD
September 14 2017
AAM Biosimilars Council Conference
Providing an overview on where the healthcare reform debate is headed, Andrew Slavitt, former head of CMS, refined the discussion to highlight the potential for biosimilars to influence the rising costs of drug products.
Industry Regulatory Experts Share Learnings From the Biosimilar Approval Process
Surabhi Dangi-Garimella, PhD
September 14 2017
AAM Biosimilars Council Conference
During a panel on the second day of the 2017 AAM Biosimilars Council Conference, held in Washington DC, regulatory leaders from Pfizer and Sandoz shared their experiences with the development of their biosimilar products: epoetin alfa (Epogen) and etanercept (Erelzi), respectively.
A European Perspective on Biosimilars
Kelly Davio
September 13 2017
AAM Biosimilars Council Conference
At the 2017 AAM Biosimilars Council Conference, Adrian van den Hoven, director general of Medicines for Europe, contradicted the conventional thinking about biosimilars, saying that biosimilars do not simply reduce costs of treatment. Instead, he said, they deliver “huge additional health benefits to patients.”
Policy Experts Weigh in on Market Access Challenges for Biosimilars
The Center for Biosimilars Staff
September 13 2017
AAM Biosimilars Council Conference
At the 2017 AAM Biosimilars Council Conference, policy experts addressed the question of how biosimilar developers can navigate the complex and challenging biologics marketplace in the United States.